Gilead Sciences Inc (GILD)
90.17
+0.41
(+0.46%)
USD |
NASDAQ |
Nov 22, 16:00
90.16
-0.01
(-0.01%)
After-Hours: 20:00
Gilead Sciences Research and Development Expense (Quarterly): 1.395B for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.395B |
| June 30, 2024 | 1.351B |
| March 31, 2024 | 3.95B |
| December 31, 2023 | 1.408B |
| September 30, 2023 | 1.457B |
| June 30, 2023 | 1.407B |
| March 31, 2023 | 1.447B |
| December 31, 2022 | -1.152B |
| September 30, 2022 | 1.149B |
| June 30, 2022 | 1.102B |
| March 31, 2022 | 3.878B |
| December 31, 2021 | 1.358B |
| September 30, 2021 | 1.101B |
| June 30, 2021 | 1.092B |
| March 31, 2021 | 1.055B |
| December 31, 2020 | 1.578B |
| September 30, 2020 | 1.158B |
| June 30, 2020 | 1.299B |
| March 31, 2020 | 1.004B |
| December 31, 2019 | 1.099B |
| September 30, 2019 | 1.03B |
| June 30, 2019 | 995.00M |
| March 31, 2019 | 1.057B |
| December 31, 2018 | 852.00M |
| September 30, 2018 | 939.00M |
| Date | Value |
|---|---|
| June 30, 2018 | 1.192B |
| March 31, 2018 | 937.00M |
| December 31, 2017 | 1.15B |
| September 30, 2017 | 789.00M |
| June 30, 2017 | 864.00M |
| March 31, 2017 | 931.00M |
| December 31, 2016 | 1.208B |
| September 30, 2016 | 1.141B |
| June 30, 2016 | 1.484B |
| March 31, 2016 | 1.265B |
| December 31, 2015 | 757.00M |
| September 30, 2015 | 743.00M |
| June 30, 2015 | 818.00M |
| March 31, 2015 | 696.00M |
| December 31, 2014 | 1.045B |
| September 30, 2014 | 630.00M |
| June 30, 2014 | 584.00M |
| March 31, 2014 | 595.00M |
| December 31, 2013 | 552.22M |
| September 30, 2013 | 546.24M |
| June 30, 2013 | 523.90M |
| March 31, 2013 | 497.63M |
| December 31, 2012 | 439.71M |
| September 30, 2012 | 465.83M |
| June 30, 2012 | 396.24M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
-1.152B
Minimum
Dec 2022
3.95B
Maximum
Mar 2024
1.407B
Average
1.325B
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.734B |
| Merck & Co Inc | 5.862B |
| Pfizer Inc | 2.598B |
| Amgen Inc | 1.45B |
| Vertex Pharmaceuticals Inc | 875.90M |